-
Tytuł:
-
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
-
Autorzy:
-
Jarius S; Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany. .
Paul F; Department of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.; NeuroCure Clinical Research Center and Clinical and Experimental Multiple Sclerosis Research Center, Berlin, Germany.
Aktas O; Department of Neurology, University of Düsseldorf, Düsseldorf, Germany.
Asgari N; Department of Neurology, University of Southern Denmark, Odense, Denmark.
Dale RC; Children's Hospital at Westmead, University of Sydney, Sydney, Australia.
de Seze J; Department of Neurology, Hôpital de Hautepierre, Strasbourg Cedex, France.
Franciotta D; IRCCS, National Neurological Institute C. Mondino, Pavia, Italy.
Fujihara K; Department of Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Jacob A; The Walton Centre, Walton Centre NHS Foundation Trust, Liverpool, UK.
Kim HJ; Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, South Korea.
Kleiter I; Department of Neurology, Ruhr University Bochum, Bochum, Germany.
Kümpfel T; Institute of Clinical Neuroimmunology, Ludwig Maximilian University, Munich, Germany.
Levy M; Department of Neurology, Johns Hopkins Hospital, Cleveland, USA.
Palace J; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.
Ruprecht K; Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Saiz A; Service of Neurology, Hospital Clinic, and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Trebst C; Department of Neurology, Hannover Medical School, Hanover, Germany.
Weinshenker BG; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Wildemann B; Molecular Neuroimmunology Group, Department of Neurology, University Hospital Heidelberg, Im Neuenheimer Feld 350, 69120, Heidelberg, Germany. .
-
Źródło:
-
Journal of neuroinflammation [J Neuroinflammation] 2018 May 03; Vol. 15 (1), pp. 134. Date of Electronic Publication: 2018 May 03.
-
Typ publikacji:
-
Journal Article; Review
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: [London] : BioMed Central, c2004-
-
MeSH Terms:
-
Internationality*
Autoantibodies/*blood
Encephalomyelitis/*blood
Encephalomyelitis/*diagnosis
Immunoglobulin G/*blood
Myelin-Oligodendrocyte Glycoprotein/*blood
Animals ; Biomarkers/blood ; Humans ; Immunoenzyme Techniques/methods ; Immunoenzyme Techniques/trends
-
References:
-
Transfusion. 1987 Nov-Dec;27(6):503. (PMID: 3318029)
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902. (PMID: 8057110)
J Neuroinflammation. 2016 Sep 27;13(1):280. (PMID: 27793206)
J Neurol. 2016 Jul;263(7):1349-60. (PMID: 27147513)
Neurology. 2015 Jul 14;85(2):177-89. (PMID: 26092914)
J Neuroinflammation. 2017 Oct 25;14 (1):208. (PMID: 29070051)
Brain Pathol. 2013 Nov;23(6):661-83. (PMID: 24118483)
Mult Scler. 2009 Dec;15(12):1466-80. (PMID: 19995844)
Brain. 2017 Mar 1;140(3):617-627. (PMID: 28364548)
Mult Scler. 2016 Apr;22(4):470-82. (PMID: 26163068)
J Immunol. 2013 Oct 1;191(7):3594-604. (PMID: 24014878)
Arch Neurol. 2008 Nov;65(11):1527-32. (PMID: 19001173)
Autoimmun Rev. 2016 Apr;15(4):307-24. (PMID: 26708342)
Neurology. 2006 May 23;66(10 ):1485-9. (PMID: 16717206)
JAMA Neurol. 2014 Mar;71(3):276-83. (PMID: 24425068)
J Neurol. 2017 Mar;264(3):453-466. (PMID: 28005176)
Mult Scler. 2016 Oct;22(12 ):1541-1549. (PMID: 26869529)
Transfusion. 2010 Dec;50(12):2577-81. (PMID: 20576011)
J Neuroinflammation. 2016 Sep 26;13(1):279. (PMID: 27788675)
J Neuroinflammation. 2012 Jan 19;9:14. (PMID: 22260418)
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257. (PMID: 27458601)
Curr Opin Neurol. 2017 Jun;30(3):295-301. (PMID: 28248700)
Rinsho Shinkeigaku. 2016 Apr 28;56(4):265-9. (PMID: 27010093)
J Neurol. 2018 Feb;265(2):424-430. (PMID: 29273846)
J Neuroinflammation. 2018 Mar 19;15(1):88. (PMID: 29554927)
Blood. 2007 May 15;109(10):4376-82. (PMID: 17264299)
J Neuroinflammation. 2016 Nov 1;13(1):281. (PMID: 27802825)
Neurology. 2012 Sep 18;79(12):1273-7. (PMID: 22914827)
Mult Scler. 1998 Jun;4(3):99-107. (PMID: 9762655)
Neuroophthalmology. 2015 Aug 25;39(5):213-219. (PMID: 27928358)
J Neuroinflammation. 2016 Nov 1;13(1):282. (PMID: 27802824)
Neurology. 2011 Aug 9;77(6):580-8. (PMID: 21795651)
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89. (PMID: 25821844)
J Neurol Sci. 2011 Jul 15;306(1-2):82-90. (PMID: 21550068)
J Neurol. 2014 Jan;261(1):17-26. (PMID: 23700317)
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 02;2(4):e131. (PMID: 26185777)
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62. (PMID: 25635259)
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. (PMID: 25364774)
Neurology. 2013 Apr 2;80(14):1330-7. (PMID: 23486868)
Brain. 2008 Nov;131(Pt 11):3072-80. (PMID: 18945724)
Lancet Neurol. 2016 Mar;15(3):317-31. (PMID: 26724102)
J Neurol. 2017 Dec;264(12 ):2420-2430. (PMID: 29063242)
J Neurol. 2017 Sep;264(9):1945-1955. (PMID: 28770374)
J Neuroinflammation. 2011 Dec 28;8:184. (PMID: 22204662)
Clin Chem Lab Med. 2010 May;48(5):659-63. (PMID: 20184532)
J Neuroophthalmol. 2013 Jun;33(2):123-7. (PMID: 23609766)
Clin Immunol. 2011 Mar;138(3):247-54. (PMID: 21169067)
Neurology. 2014 Feb 11;82(6):474-81. (PMID: 24415568)
J Neurol Sci. 2015 Aug 15;355(1-2):59-63. (PMID: 26026942)
Ann Clin Transl Neurol. 2015 Mar;2(3):295-301. (PMID: 25815356)
Mult Scler. 1998 Jun;4(3):111-7. (PMID: 9762657)
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163. (PMID: 26516628)
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136. (PMID: 27951522)
Ann Neurol. 2014 Mar;75(3):411-28. (PMID: 24700511)
Neurology. 2017 Jul 11;89(2):207-209. (PMID: 28600462)
J Neurol Sci. 2016 Apr 15;363:182-7. (PMID: 27000248)
J Neurol. 2018 Apr;265(4):845-855. (PMID: 29423614)
Mult Scler. 2017 Sep;23 (10 ):1377-1384. (PMID: 27885065)
Brain Dev. 2015 Jan;37(1):145-8. (PMID: 24582475)
JAMA Neurol. 2018 Apr 1;75(4):478-487. (PMID: 29305608)
Eur J Neurol. 2016 Mar;23 (3):580-7. (PMID: 26593750)
No To Hattatsu. 2016 May;48(3):199-203. (PMID: 27349083)
J Neuroimmunol. 2016 Apr 15;293:28-33. (PMID: 27049558)
J Neuroimmunol. 2017 Apr 15;305:19-28. (PMID: 28284341)
Brain. 2017 Dec 1;140(12 ):3128-3138. (PMID: 29136091)
Mult Scler Relat Disord. 2018 Feb;20:144-152. (PMID: 29414288)
Mult Scler. 2008 Nov;14(9):1157-74. (PMID: 18805839)
Mult Scler. 2015 Jun;21(7):866-874. (PMID: 25344373)
Neurology. 2015 Jul 14;85(2):118-9. (PMID: 26092912)
J Neurol Sci. 2017 Oct 15;381:240-244. (PMID: 28991690)
-
Contributed Indexing:
-
Keywords: Antibody testing; Consensus recommendations; Diagnosis; Multiple sclerosis (MS); Myelin oligodendrocyte glycoprotein (MOG) antibodies; Neuromyelitis optica spectrum disorders (NMOSD); Optic neuritis (ON), Myelitis
-
Substance Nomenclature:
-
0 (Autoantibodies)
0 (Biomarkers)
0 (Immunoglobulin G)
0 (MOG protein, human)
0 (Myelin-Oligodendrocyte Glycoprotein)
-
Entry Date(s):
-
Date Created: 20180505 Date Completed: 20190415 Latest Revision: 20220408
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC5932838
-
DOI:
-
10.1186/s12974-018-1144-2
-
PMID:
-
29724224
-
Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM ("red flags") that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.